Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy

Masahiro Yamashita; Hisao Higo; Nobuharu Fujii; Chiaki Matsumoto; Go Makimoto; Kiichiro Ninomiya; Masanori Fujii; Kammei Rai; Eiki Ichihara; Kadoaki Ohashi; Katsuyuki Hotta; Masahiro Tabata; Yoshinobu Maeda; Nobuaki Miyahara

Respiratory Medicine Case Reports (Jan 2024)

Protracted coronavirus disease 2019 after chimeric antigen receptor-T cell therapy successfully treated with sequential multidrug therapy

Masahiro Yamashita,
Hisao Higo,
Nobuharu Fujii,
Chiaki Matsumoto,
Go Makimoto,
Kiichiro Ninomiya,
Masanori Fujii,
Kammei Rai,
Eiki Ichihara,
Kadoaki Ohashi,
Katsuyuki Hotta,
Masahiro Tabata,
Yoshinobu Maeda,
Nobuaki Miyahara

Affiliations

Masahiro Yamashita: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan
Hisao Higo: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan; Corresponding author. Department of Allergy and Respiratory Medicine, Okayama University Hospital, 2Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
Nobuharu Fujii: Department of Hematology and Oncology, Okayama University Hospital, Japan
Chiaki Matsumoto: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan
Go Makimoto: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan
Kiichiro Ninomiya: Center for Comprehensive Genomic Medicine, Okayama University Hospital, Japan
Masanori Fujii: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan
Kammei Rai: Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
Eiki Ichihara: Center for Clinical Oncology, Okayama University Hospital, Japan
Kadoaki Ohashi: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan
Katsuyuki Hotta: Center for Innovative Clinical Medicine, Okayama University Hospital, Japan
Masahiro Tabata: Center for Clinical Oncology, Okayama University Hospital, Japan
Yoshinobu Maeda: Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Nobuaki Miyahara: Department of Allergy and Respiratory Medicine, Okayama University Hospital, Japan; Department of Medical Technology, Okayama University Academic Field of Health Sciences, Japan

Journal volume & issue: Vol. 51
p. 102104

Abstract

Read online

A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she experienced persistent fatigue and cough and fever in June. Computed tomography revealed bilateral ground-glass opacities (GGO), and the patient was treated with corticosteroids for organizing pneumonia after COVID-19. Partial improvement was observed, but new GGO appeared despite corticosteroid therapy. Genome analysis of severe acute respiratory syndrome coronavirus 2 detected Omicron variant BA.1.1.2, which was prevalent at the time of initial infection. The patient was diagnosed with protracted COVID-19 and was treated with remdesivir, molnupiravir, nirmatrelvir/ritonavir, and tixagevimab/cilgavimab. These treatments appeared to contribute to the improvement of protracted COVID-19.

Published in Respiratory Medicine Case Reports

ISSN: 2213-0071 (Online)
Publisher: Elsevier
Country of publisher: Netherlands
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the respiratory system
Website: http://www.journals.elsevier.com/respiratory-medicine-case-reports/

About the journal

Abstract

Keywords